Neuronoff

Neuronoff operates at the intersection of neuromodulation, medical devices, and chronic-pain therapeutics. Its core differentiation is the Injectrode® concept: an injectable metal electrode designed to create a neuromodulation interface inside the body through a small needle, potentially avoiding the larger incisions associated with conventional implanted electrodes. The platform is paired with an external pulse generator, physician programmer, and patch electrodes, creating a complete treatment system rather than a standalone implant. The company’s 2026 multi-site implantable pulse generator compatibility announcement broadens the addressable use cases beyond spinal cord stimulation, while the Department of Defense-funded neurogenic-bladder trial provides evidence of application outside pain management. Neuronoff’s market position is therefore best understood through its technology and clinical-development strategy: a minimally invasive electrode platform pursuing multiple anatomical targets and indications. Its principal constraints remain clinical validation, regulatory execution, and adoption against established neuromodulation systems.

Neuronoff’s trajectory shows a transition from research funding to clinical and commercialization preparation. The company raised a $2.2 million grant on Oct 31, 2019, followed by a $5 million grant on Jan 30, 2025 and a $4.5 million financing round on Oct 7, 2025. The 2025 financing was tied to preparing the Injectrode® platform for chronic-pain launch, marking an inflection point from platform development toward market entry. In 2026, the company demonstrated multi-site implantable pulse generator compatibility on Mar 16, 2026 and implanted the first patient in a Department of Defense-funded neurogenic-bladder trial on Jun 5, 2026. Those events suggest expanding clinical scope and technical compatibility rather than reliance on a single indication. Hiring across science, engineering, technical, and data roles is consistent with a company building clinical, manufacturing, and regulatory capacity. However, public information does not provide verified headcount growth, commercial revenue, regulatory-clearance dates, or confirmed launch timing, so the trajectory remains primarily milestone- and funding-driven.